Topic
49 stories
The global specialist HIV company ViiV Healthcare has entered a global collaboration and license agreement with Halozyme for ENHANZE. Halozyme’s drug delivery technology provides the opportunity to administer large volume subcutaneous injections that may enable dosing intervals of every three months and up to six months or longer for ViiV’s pipeline of HIV medicines. The […]
The health ministry of UAE has started Sinopharm covid vaccine trial for children below 18 Some members of Abu Dhabi’s ruling family had participated in the trial which administered China’s Sinopharm COVID-19 vaccine to children. The UAE in May approved the Pfizer-BioNTech vaccine for emergency use in children aged 12-15. Dubai, the second-largest member of […]
GlaxoSmithKline and iTeos Therapeutics to co-develop and co-commercialise the treatment for patients with cancer . Currently EOS-448, an anti-TIGIT monoclonal antibody is in phase one development, TIGIT which is a part of the CD226 checkpoint axis, has exhibited potential as a hopeful target for the next generation of immuno-oncology therapies based on compelling preclinical data […]
BioNTech and Pfizer has announced its plans to provide 500 million doses to U.S government at a non profit price. Approximately around 200 million doses in 2021 and 300 million by the first half of 2022. These doses from Pfizer and BioNTech will be donated to low and lower middle income countries including the African […]
The new treatment for Alzheimer’s disease has been approved by the regulators of USA nearly after 20 years. This approval will trigger pressure to make it available worldwide despite of its mixed evidence over its efficacy. Aducanumab targets the Underlying cause of Alzheimer’s, the most common form of dementia. Food and Drug Administration (FDA) of […]
The American multinational Carlyle Group buys UK pharmaceuticals Vectura Group for £958 million. Around 136 pence in cash plus a dividend of 19 pence for each share under the terms of the offer representing a 32% premium on the ex-dividend closing price of the stock. The chairman of Vectura group Bruno Angelici said: “Vectura has […]
The United Arab Emirates (UAE) and Bahrain to offer Sinopharm vaccine shots to residents which is developed by China. These booster shots which is given to the residents and citizens had two doses, stated by the countries medical authorities. The announcements come after the questions raised over Sinopharm’s reports of the pandemic Covid-19 and efficacy […]
The Biotech company Ginkgo Bioworks merges with Harry Sloan in $17.5 billion deal SPAC deal, the firm found by Harry Sloan is Soaring Eagle Acquisition Corp. Boston based Ginkgo Bioworks is also backed by Bill Gates private investment firm Cascade Investment. The company also received $1.1 billion loan from the U.S. Government for COVID-19 testing […]
The American multinational pharmaceutical corporation Pfizer and German biotechnology company BioNTECH to donate doses of the companies’ COVID-19 Vaccine to help vaccinate athletes and their delegations participating in 2020 Tokyo Games, which is scheduled to begin on July 2021. Both the companies have signed Memorandum of Understanding (MoU) with the International Olympic Committee (IOC) to […]
The British-Swedish multinational pharmaceutical and biotechnology company, AstraZeneca, has made a staggering $275 million in revenue in first quarter from its Covid-19 vaccine. The revenue from Covid-19 Vaccine came by delivering 68 million doses Worldwide, Sales in Europe were $224 million, market sales were $43 million, and $8 million in the rest of the world. […]
The South Korean biotechnology company, Samsung Biologics and commercial stage biopharmaceutical company, TG Therapeutics said that it has expanded a large-scale contract manufacturing deal for the supply of TG Therapeutics’ ublituximab. The company Samsung Biologics said it is currently building its fourth and largest biomanufacturing facility in Incheon, Korea. The biopharmaceutical company, TG Therapeutics has […]
The biotechnology company RubrYc Therapeutics partners with commercial stage biopharmaceutical company Zai Lab for research collaboration and license option agreement. This collaboration will allow RubrYc’s Meso-scale Engineered Molecules (MEMs) platform, to identify monoclonal antibodies with enhanced biological function for an undisclosed oncology target. Under the terms of the agreement RubrYc and Zai Labs will collaborate […]
